Can-Fite BioPharma (CANF) investor relations material

Company overview and business model

• Advanced clinical-stage biopharmaceutical company developing orally bioavailable small molecule therapeutics targeting the A3 adenosine receptor (A3AR) for cancer, liver, and inflammatory diseases, as well as erectile dysfunction.

• Product pipeline includes CF101 (Piclidenoson) for psoriasis and Lowe syndrome, CF102 (Namodenoson) for HCC, MASH, and pancreatic cancer, and CF602 for erectile dysfunction.

• Out-licensing strategy for commercialization, with partnerships in Canada, Europe, China, South Korea, and Central Eastern Europe.

• No commercial sales to date; focus on advancing clinical trials and expanding indications for existing molecules.

Financial performance and metrics

• As of June 30, 2026, shareholders' equity was $4.86 million (actual) and $8.79 million (pro forma, post-warrant repricing).

• 6,063,093 ordinary shares outstanding as of September 25, 2026; up to 12,652,889 shares if all warrants are exercised.

• Since inception, significant losses have been incurred due to research and development activities.

Use of proceeds and capital allocation

• No proceeds from the resale of ADSs by selling shareholders; proceeds from warrant exercises (if not cashless) could total up to $8.31 million.

• Any proceeds from warrant exercises will be used for research and development, general and administrative expenses, and working capital.

• Pending use, proceeds will be invested in short-term, interest-bearing securities or U.S. government obligations.